Mizuho Securities adjusts price target for intra-cellular therapies to $72 from $75, maintains buy rating
Newswires MT 2022
|
||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
|
|
|
|
|
||||
|
||||
Technical Analysis Trends INTRA-CELLULAR THERAPIES, INC.
Short term | Middle term | Long term | |
Tendencies | Neutral | Neutral | Bullish |
Evolution of the income statement
Sale ![]() To buy |
|
Medium consensus | TO BUY |
Number of analysts | 14 |
Last closing price | $59.19 |
Average target price | $70.31 |
Average Spread / Target | 18.8% |
Comments are closed.